IP Intelligence

Home | IP Intelligence

<img class="alignright wp-image-2343 size-medium" src="https://ipintelligencereport.bakerhostetlerblogs.com/wp-content/uploads/sites/11/2015/11/Pills_178995579-300x200.jpg" alt="Pharmacy concept" width="300" height="200" />

Efforts to extend the life cycle of pharmaceutical products frequently involve innovations and improvements in product design, formulation, route of administration and treatment indications. In addition, negotiation of agreements with competitors, including generic and biosimilar manufacturers, is frequently employed as part of a life cycle management strategy. However, recent changes in patent, regulatory and antitrust laws have introduced greater complexity and higher risk into these strategies.

On October 23, 2015, a distinguished panel of BakerHostetler partners led an exclusive seminar in person and online at which they discussed these and related issues and provided suggestions for developing successful life cycle management strategies. Partners Carl Hittinger, Lee Rosebush, Lance Shea and Maurice Valla are all deeply knowledgeable attorneys with decades of experience in helping clients meet their pharmaceutical business objectives.

We are delighted to share with you a brief on the seminar highlights, and hope you enjoy these insider perspectives on issues and approaches for developing successful life cycle management strategies.

<a href="http://bakerlaw.com/files/uploads/News/Articles/LITIGATION/FDA/Brief-Pharmaceutical-Life-Cycle-Management.pdf">Read the brief</a>.

Individual pieces are also available for each attorney here:
<ul>
	<li><a href="http://bakerlaw.com/files/uploads/News/Articles/LITIGATION/FDA/Valla-Patent-Exclusivity-02-08-2016.pdf">Patent-Based Exclusivity</a> by S. Maurice Valla</li>
	<li><a href="http://bakerlaw.com/files/uploads/News/Articles/LITIGATION/FDA/Rosebush-Exclusivities-02-08-2016.pdf">Five Types of Exclusivities</a> by Lee H. Rosebush</li>
	<li><a href="http://bakerlaw.com/files/uploads/News/Articles/LITIGATION/FDA/Hittinger-Antitrust-Web-02-08-2016.pdf">Antitrust Considerations in Pharmaceutical Life Cycle Management</a> by Carl W. Hittinger</li>
	<li><a href="http://bakerlaw.com/files/uploads/News/Articles/LITIGATION/FDA/Shea-ANDA-Litigation-02-08-2016.pdf">ANDA Approval Litigation: Arguing for Practical Exclusivity</a> by Lance L. Shea</li>
</ul>

Pharmaceutical Life Cycle Management: Navigating the New IP, FDA and Antitrust Terrain